Key clinical point: Proton pump inhibitor (PPI) use is significantly associated with an increased risk for gastric cancer.
Major finding: PPI users vs nonusers were significantly more likely to develop gastric cancer (odds ratio 1.75; 95% CI 1.28-2.40).
Study details: This study meta-analyzed 16 observational studies (cohort and case-control studies; n = 2,936,935) that evaluated the association between PPI use and the risk for gastric cancer.
Disclosures: This study was sponsored by grants from the Taipei Tzu Chi Hospital and Buddhist Tzu Chi Medical Foundation, Taiwan. The authors declared no conflicts of interest.
Source: Peng TR et al. Association between proton-pump inhibitors and the risk of gastric cancer: A systematic review and meta-analysis. Int J Clin Oncol. 2022 (Oct 12). Doi: 10.1007/s10147-022-02253-2